KalVista Pharmaceuticals, Inc.
DelistedCIK 1348911fmd_0DTH027R3AZKX0FT4FHVS7FJH9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Mar 31, 2026, 57 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 2 | 8 | 16 | 13 | – | – | – | 50 | – |
| Research and development | 15 | 13 | 18 | 35 | 40 | 41 | 70 | 80 | 86 | 72 |
| Total operating expenses | 17 | 24 | 27 | 46 | 53 | 58 | 97 | 111 | 140 | 188 |
| Operating income | (15) | (22) | (19) | (30) | (41) | (58) | (97) | (111) | (140) | (188) |
| Interest expense | – | – | – | – | – | – | – | – | – | 6 |
| Interest and investment income | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 2 | 4 | 6 |
| Other non-operating income (expense) | 4 | 4 | 3 | 9 | 11 | 12 | 14 | 18 | 14 | 8 |
| Income before taxes | (11) | (19) | (16) | (21) | (29) | (82) | (82) | (93) | (127) | (180) |
| Income tax expense | 0 | 0 | 0 | 0 | (0) | 0 | 0 | 0 | 0 | 3 |
| Net income from continuing operations | (11) | (19) | (16) | (21) | (29) | (82) | (82) | (93) | (127) | (183) |
| Net income | (11) | (19) | (16) | (21) | (29) | (46) | (82) | (93) | (127) | (183) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |